Icotrokinra: A Promising Oral IL-23 Receptor Inhibitor for Moderate-to-Severe Plaque Psoriasis
用户1AV4o0WC3uSU
14天前
61
10
已关闭
DOI:
文献链接:
其他信息:
F Okundia, M Shakhashiro
Skin therapy letter, 2026
pubmed.ncbi.nlm.nih.gov
Biologics have emerged in recent years as relatively safe and effective options for managing plaque psoriasis, however, a subset of patients remain reluctant to initiate biologic therapy. Icotrokinra is a novel, first-in-class oral peptide that targets the interleukin-23 receptor and has demonstrated a favorable safety and efficacy profile comparable to that of injectable biologics in individuals aged 12 years and older. This review summarizes the clinical trial data regarding the safety and efficacy of icotrokinra.
